Table 1.
Baseline characteristics in the recurrence and non-recurrence.
| Patients with No Recurrence (n = 153) | Patients with Ipsilateral Recurrence (n = 10) | p-Value | |
|---|---|---|---|
| Age | 52.9 ± 9.8 | 46.5 ± 7.5 | 0.05 |
| Last outpatient follow-up (months) | 82.2 ± 26.5 | 51.7 ± 36.1 | 0.009 |
| Surgery type | 0.109 | ||
| Total mastectomy | 100 | 9 | |
| BCS | 53 | 1 | |
| Radiation therapy | 0.343 | ||
| No | 100 | 8 | |
| Yes | 53 | 2 | |
| Endocrine therapy | 0.607 | ||
| No | 111 | 8 | |
| Yes | 42 | 2 | |
| DCIS size | 2.51 ± 1.89 | 2.35 ± 1.99 | 0.814 |
| DCIS nuclear grade | 0.075 | ||
| Non-high | 75 | 2 | |
| High | 78 | 8 | |
| Comedo necrosis | 0.128 | ||
| Negative | 50 | 1 | |
| Positive | 101 | 9 | |
| ER | 0.078 | ||
| Negative | 115 | 7 | |
| Positive | 38 | 3 | |
| PR | 0.765 | ||
| Positive | 100 | 7 | |
| Negative | 53 | 3 | |
| HER2 | 0.479 | ||
| Negative | 108 | 6 | |
| Positive | 45 | 4 | |
| Ki-67 (%) | 0.669 | ||
| <14% | 94 | 5 | |
| ≥14% | 56 | 4 | |
| IHC type | 0.562 | ||
| Luminal | 114 | 7 | |
| HER2-enriched | 26 | 3 | |
| Basal-like | 12 | 0 | |
| VNPG | |||
| Low risk | 38 | 1 | 0.287 |
| Non-low risk | 115 | 9 | |
| Comet classification | 0.031 | ||
| Low risk | 68 | 1 | |
| Non-low risk | 84 | 9 | |
| Resection margin (2 mm) | 0.078 | ||
| Negative | 136 | 7 | |
| Positive | 17 | 3 | |
| Fibroglandular tissue (FGT) | 0.743 | ||
| Almost entirely fat, Scattered | 54 | 3 | |
| Heterogenoues, Extreme | 99 | 7 | |
| Background parenchymal enhancement (BPE) | 0.028 | ||
| Minimal, Mild | 122 | 5 | |
| Mild, Marked | 31 | 5 |
Results are presented as number (percentage) for categorical variables and mean (SD) for continuous variables. p values were calculated using Chi-square test or Fisher’s exact test for categorical variables and Wilcoxon rank sum test for continuous variables.